Not all biomarkers are the same
Every man with prostate cancer deserves a better answer
Not all biomarker tests are the same. When it comes to making active surveillance or definitive treatment decisions, selecting the correct biomarker test matters. The Prolaris® test from Myriad Genetics is the only biomarker test on the market with both an Active Surveillance Threshold and a Multi-Treatment Modality Threshold.
Endpoints matter when selecting a biomarker
It is critical to understand what information you are getting when selecting a biomarker. The Prolaris test looks at the disease endpoints that matter most and has been rigorously studied and proven to meet ALL of its primary endpoints.
Prolaris endpoints
10-year disease-specific mortality when considering conservative management
10-year risk of developing metastasis when considering definitive treatment